2016 American Society of Hematology Annual Meeting*

December 3-6, 2016; San Diego, California
Elias Jabbour, MD, and Farhad Ravandi, MD, review data from key leukemia presentations at the 2016 American Society of Hematology Annual Meeting.
Elias Jabbour, MD
Farhad Ravandi, MD

Leukemias

Results from a phase Ib trial combining vadastuximab talirine to 7 + 3 induction therapy suggests deeper and more rapid remissions, without added nonhematologic toxicity, for patients with newly diagnosed AML.

Released: December 5, 2016

Phase II trial suggests durable, MRD-negative CR in 82% of patients after infusion of CTL019 CAR T-cells.

Released: December 9, 2016

In this subanalysis of the phase III TOWER study, blinatumomab demonstrated superior health-related QoL vs standard-of-care chemotherapy in patients with R/R Ph- B-Precursor ALL.

Released: December 6, 2016

The combination of inotuzumab ozogamicin with lower-intensity mini-HCVD chemotherapy in older patients with ALL resulted in a high ORR and low early mortality.

Released: December 7, 2016

In this phase I trial, vadastuximab talirine plus HMA was active in higher-risk patient subsets, including patients with advanced secondary AML and those older than 75 years of age.

Released: December 8, 2016

ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations.

Released: December 7, 2016

In this phase II open-label study, the combination of ponatinib with hyper-CVAD resulted in high complete cytogenetic and molecular response rates in patients with Ph+ ALL.

Released: December 12, 2016

Factors associated with MRFS after TKI cessation included longer durations of imatinib therapy, MR4, and pretreatment IFN.

Released: December 9, 2016

In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger.

Released: December 8, 2016

In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at Hematology 2016 in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia.

Elias Jabbour, MD Farhad Ravandi, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 13, 2017 Expiration: February 12, 2018

In this downloadable slideset, Elias Jabbour, MD, and Farhad Ravandi, MD, review key studies and data presented at the 2016 American Society of Hematology annual meeting relevant to the management of patients with acute or chronic leukemias.

Released: December 20, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?